Vanguard Group Inc. cut its position in shares of C.R. Bard, Inc. (NYSE:BCR) by 1.0% in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 7,799,322 shares of the medical instruments supplier’s stock after selling 82,142 shares during the period. Vanguard Group Inc. owned approximately 10.73% of C.R. Bard worth $2,465,443,000 at the end of the most recent quarter.
Several other hedge funds have also recently added to or reduced their stakes in BCR. UBS Asset Management Americas Inc. boosted its stake in shares of C.R. Bard by 10.2% during the 1st quarter. UBS Asset Management Americas Inc. now owns 294,759 shares of the medical instruments supplier’s stock worth $73,259,000 after purchasing an additional 27,308 shares during the period. Karp Capital Management Corp bought a new stake in C.R. Bard during the 1st quarter valued at about $16,849,000. Sei Investments Co. lifted its holdings in C.R. Bard by 5.4% during the 1st quarter. Sei Investments Co. now owns 37,359 shares of the medical instruments supplier’s stock valued at $9,285,000 after buying an additional 1,900 shares in the last quarter. TD Asset Management Inc. lifted its holdings in C.R. Bard by 1.5% during the 1st quarter. TD Asset Management Inc. now owns 103,926 shares of the medical instruments supplier’s stock valued at $25,830,000 after buying an additional 1,576 shares in the last quarter. Finally, Neuburgh Advisers LLC lifted its holdings in C.R. Bard by 4.7% during the 1st quarter. Neuburgh Advisers LLC now owns 6,766 shares of the medical instruments supplier’s stock valued at $1,681,000 after buying an additional 306 shares in the last quarter. 79.22% of the stock is owned by hedge funds and other institutional investors.
C.R. Bard, Inc. (NYSE:BCR) traded up 0.011% during midday trading on Thursday, hitting $318.595. 53,833 shares of the stock traded hands. C.R. Bard, Inc. has a 12-month low of $203.63 and a 12-month high of $324.58. The company’s 50-day moving average is $320.07 and its 200 day moving average is $299.22. The firm has a market cap of $23.15 billion, a P/E ratio of 41.827 and a beta of 0.60.
C.R. Bard (NYSE:BCR) last announced its earnings results on Thursday, July 27th. The medical instruments supplier reported $2.92 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $2.84 by $0.08. The company had revenue of $979.70 million during the quarter, compared to analyst estimates of $976.53 million. C.R. Bard had a net margin of 14.99% and a return on equity of 48.70%. C.R. Bard’s revenue was up 5.2% compared to the same quarter last year. During the same quarter last year, the firm posted $2.54 earnings per share. On average, analysts anticipate that C.R. Bard, Inc. will post $11.84 EPS for the current fiscal year.
In other C.R. Bard news, insider John P. Groetelaars sold 23,687 shares of the stock in a transaction dated Thursday, August 10th. The shares were sold at an average price of $318.73, for a total transaction of $7,549,757.51. Following the completion of the transaction, the insider now owns 31,445 shares of the company’s stock, valued at $10,022,464.85. The sale was disclosed in a legal filing with the SEC, which is available at this link. Company insiders own 0.80% of the company’s stock.
A number of equities research analysts recently weighed in on the stock. BidaskClub upgraded shares of C.R. Bard from a “buy” rating to a “strong-buy” rating in a report on Saturday, July 8th. Zacks Investment Research upgraded shares of C.R. Bard from a “hold” rating to a “buy” rating and set a $351.00 price objective for the company in a report on Tuesday, June 6th. Jefferies Group LLC reiterated a “hold” rating and set a $317.00 price objective on shares of C.R. Bard in a report on Thursday, September 14th. Finally, BMO Capital Markets reiterated a “hold” rating and set a $317.00 price objective on shares of C.R. Bard in a report on Tuesday, July 11th. One equities research analyst has rated the stock with a sell rating, eight have issued a hold rating and one has issued a strong buy rating to the stock. C.R. Bard presently has an average rating of “Hold” and an average price target of $292.00.
TRADEMARK VIOLATION WARNING: “C.R. Bard, Inc. (BCR) Position Lowered by Vanguard Group Inc.” was originally reported by Chaffey Breeze and is owned by of Chaffey Breeze. If you are viewing this article on another publication, it was stolen and republished in violation of US and international trademark and copyright laws. The correct version of this article can be viewed at https://www.chaffeybreeze.com/2017/09/21/c-r-bard-inc-bcr-position-lowered-by-vanguard-group-inc.html.
C.R. Bard Profile
C. R. Bard, Inc (Bard) is engaged in designing, manufacturing, packaging, distribution and sale of medical, surgical, diagnostic and patient care devices. The Company operates through the manufacture and sale of medical devices segment. It sells a range of products to hospitals, individual healthcare professionals, extended care facilities and alternate site facilities on a global basis.
Want to see what other hedge funds are holding BCR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for C.R. Bard, Inc. (NYSE:BCR).
Receive News & Ratings for C.R. Bard Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for C.R. Bard Inc. and related companies with MarketBeat.com's FREE daily email newsletter.